CompaniesVolpi Group
Volpi Group logo

Volpi Group

active
Dietikon, Switzerland
Founded 1953
Website
About

Diagnostic Instruments

Areas of Focus

Categories

Diagnostics
Team (7)
Christoph Bohli
Christoph Bohli
CEO and Member of the Board
Volpi Group
executive
Christoph Dürmüller
Christoph Dürmüller
Member of the Board
Volpi Group
team_member
Marco Gadola
Marco Gadola
Chairman of the Board
Volpi Group
board_chair
Max Kunz
Max Kunz
Vice-Chairman of the Board and Owner
Volpi Group
board_chair
Richard Ritter
Richard Ritter
Chief Financial Officer
Volpi Group
executive
Simon Langhart
Simon Langhart
Head of Sales and Marketing
Volpi Group
team_member
View all 7 team members →
Clinical Trials (25)
View all

Total Trials

25

As Lead Sponsor

20

As Collaborator

5

Total Enrollment

3,631

By Phase

PHASE1/PHASE2: 3PHASE3: 3PHASE2: 6PHASE1: 11PHASE2/PHASE3: 2

By Status

COMPLETED: 11RECRUITING: 7TERMINATED: 5ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline25 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Today
NCT01287585
NCT01497925
NCT01910025
NCT02029690
NCT02102022
NCT02709512
NCT03970447
NCT04587830
NCT05616624
NCT05842512
NCT05712694
NCT05813327
Hover over trial bars to see details

Recent Trials

NCT05813327Collaborator
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
PHASE1/PHASE2Recruiting
35 participants
Started: Mar 14, 2024 · Completed: Jan 15, 2029
NCT05712694Lead Sponsor
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
PHASE3Recruiting
300 participants
Started: Nov 29, 2023 · Completed: Dec 30, 2027
NCT05842512Lead Sponsor
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
PHASE2Recruiting
60 participants
Started: Sep 13, 2023 · Completed: Jan 31, 2028
NCT05616624Collaborator
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
PHASE1/PHASE2Recruiting
114 participants
Started: Apr 5, 2023 · Completed: Dec 31, 2033
NCT05001828Lead Sponsor
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
PHASE1Recruiting
60 participants
Started: Apr 5, 2022 · Completed: Dec 31, 2025
View all 25 trials →
Locations (1)
Headquarters
Dietikon, Switzerland
Map

Loading map...